In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospects of a molecule tipped to ...

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

NeuroQure, a startup diagnostics medtech that formed in 2023, has launched a first-of-its-kind test that can identify autism ...

The National Institutes of Health (NIH) has reinstated a ban on the research use of human fetal tissue (HFT) obtained from abortions, a prohibition originally put in place during President Trump’s ...

Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...